Stock A087010 PEPTRON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Peptron, Inc.

Equities

A087010

KR7087010005

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
30,750 KRW +1.15% Intraday chart for Peptron, Inc. +6.03% -23.60%
2023 Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal MT
2023 Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 373,967 299,633 251,355 228,958 157,795 830,231
Enterprise Value (EV) 1 366,800 311,222 216,703 207,878 149,778 834,381
P/E ratio -100 x -16.9 x -13.7 x -15.2 x -10.5 x -52 x
Yield - - - - - -
Capitalization / Revenue 96.8 x 166 x 80.5 x 34.6 x 27.1 x 248 x
EV / Revenue 95 x 173 x 69.4 x 31.4 x 25.8 x 250 x
EV / EBITDA -52.4 x -31 x -15.1 x -17.1 x -14.7 x -64.2 x
EV / FCF -30 x -28.8 x -20.7 x -33.4 x -12.6 x -150 x
FCF Yield -3.33% -3.47% -4.83% -3% -7.93% -0.67%
Price to Book 8.29 x 10.7 x 4.39 x 3.68 x 2.97 x 22.9 x
Nbr of stocks (in thousands) 15,327 15,327 15,327 20,627 20,627 20,627
Reference price 2 24,400 19,550 16,400 11,100 7,650 40,250
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,862 1,801 3,121 6,625 5,814 3,342
EBITDA 1 -7,006 -10,052 -14,340 -12,149 -10,172 -12,990
EBIT 1 -7,906 -12,704 -17,606 -15,659 -15,227 -15,884
Operating Margin -204.72% -705.32% -564.17% -236.37% -261.9% -475.3%
Earnings before Tax (EBT) 1 -3,697 -17,626 -18,335 -15,284 -15,067 -15,941
Net income 1 -3,726 -17,718 -18,382 -15,042 -15,063 -15,922
Net margin -96.48% -983.7% -589.03% -227.07% -259.08% -476.43%
EPS 2 -243.1 -1,156 -1,196 -729.2 -730.3 -774.0
Free Cash Flow 1 -12,225 -10,791 -10,469 -6,226 -11,877 -5,568
FCF margin -316.56% -599.13% -335.48% -93.98% -204.29% -166.62%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 11,589 - - - 4,150
Net Cash position 1 7,166 - 34,652 21,080 8,017 -
Leverage (Debt/EBITDA) - -1.153 x - - - -0.3195 x
Free Cash Flow 1 -12,225 -10,791 -10,469 -6,226 -11,877 -5,568
ROE (net income / shareholders' equity) -7.92% -48.4% -34.9% -21.6% -26.1% -35.7%
ROA (Net income/ Total Assets) -7.92% -12% -12.3% -10% -13% -16.4%
Assets 1 47,057 148,110 149,251 150,297 115,657 96,848
Book Value Per Share 2 2,943 1,833 3,739 3,020 2,575 1,761
Cash Flow per Share 2 117.0 160.0 3,295 225.0 244.0 208.0
Capex 1 10,136 5,007 3,098 699 1,525 731
Capex / Sales 262.46% 277.98% 99.27% 10.55% 26.23% 21.88%
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PEPTRON, INC. Stock Peptron, Inc.
-23.60% 465M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 108B
ARGENX SE Stock argenx SE
-2.56% 23.46B
BIONTECH SE Stock BioNTech SE
-14.60% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.53B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.81B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A087010 Stock
  4. Financials Peptron, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW